Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Dusseldorf - Delayed Quote EUR

Indivior PLC (2IVB.DU)

Compare

9.05

-0.10

(-1.09%)

As of 4:32:06 PM GMT+1. Market Open.

Indivior Announces Further Changes to Board of Directors

Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 202

PR Newswire 2 days ago

INDV
Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Indivior PLC (NASDAQ:INDV) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head of European […]

Insider Monkey 3 days ago

INDV

LLY
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May 2025.

PR Newswire 7 days ago

INDV
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the treatment of moderate to severe opioid use disorder (OUD).

PR Newswire 10 days ago

INDV
Indivior Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Indivior ( LON:INDV ) Full Year 2024 Results Key Financial Results Revenue: US$1.19b (up 8.7% from FY 2023). Net loss...

Simply Wall St. 12 days ago

INDV
Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ...

Indivior PLC (INDV) reports a 20% increase in SUBLOCADE net revenue for 2024, while implementing significant cost-saving measures to enhance financial flexibility.

GuruFocus.com 13 days ago

INDV
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior Plc (NASDAQ:INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations. Addiction and mental illnesses-focused Indivior reported fourth-quarter sales of $298 million, up 2% year over year, beating the consensus of $259.3 million. The London-based healthcare firm reported adjusted EPS of 32 cents, down from 43 a year ago, beating the consensus of 21 cents. In the fourth quarter, adjusted operating profit remained unchanged at $66 million,

Benzinga 13 days ago

INDV
Indivior PLC (INDV) Q4 Earnings Meet Estimates

Indivior (INDV) delivered earnings and revenue surprises of 0% and 13.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 14 days ago

INDV
Indivior Announces FY and Q4 2024 Financial Results

Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

PR Newswire 14 days ago

INDV
Stocks to watch this week: Alibaba, Walmart, HSBC, Rio Tinto and Lloyds

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 20 days ago

RIO

RTNTF

RTPPF
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 21 days ago

INDV

KPTI
Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV)

Summers Value Partners, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net1 return of 27.4% in 2024 outperforming 11.3% return for its primary benchmark, the Russell 2000 Index ETF (IWM). The fund also outperformed its secondary […]

Insider Monkey last month

INDV

^RUT
Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...

Simply Wall St. last month

INDV
Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...

Simply Wall St. 2 months ago

INDV
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Despite a dip in revenue, Addex Therapeutics Ltd (ADXN) advances its drug development programs and strengthens its financial position through strategic collaborations.

GuruFocus.com 3 months ago

INDV
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE® (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inj

PR Newswire 3 months ago

INDV
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.

PR Newswire 3 months ago

INDV
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate the importance of access to medications for the treatment of opioid use disorder (MOUD) and the effectiveness and safety of SUBLOCADE® in the treatment of OUD. These data add to the growing body of evidence that SUBLOCADE can improve outcomes, such as abstinence, retention, and recovery in persons with OUD.

PR Newswire 4 months ago

INDV
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

Indivior PLC (INDV) reports a 13% increase in total net revenue and a 62% rise in adjusted operating profit, while navigating competitive pressures and strategic cost reductions.

GuruFocus.com 4 months ago

INDV
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of 38.46% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

INDV

Performance Overview

Return	2IVB.DU	FTSE 100
YTD	-23.31%	+6.24%
1-Year	-54.75%	+13.07%
3-Year	-44.65%	+24.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Indivior PLC (2IVB.DU)

Indivior Announces Further Changes to Board of Directors

Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now?

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ...

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior PLC (INDV) Q4 Earnings Meet Estimates

Indivior Announces FY and Q4 2024 Financial Results

Stocks to watch this week: Alibaba, Walmart, HSBC, Rio Tinto and Lloyds

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV)

Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Performance Overview